VYNE Therapeutics Inc (NASDAQ: VYNE) on Monday, plunged -6.34% from the previous trading day, before settling in for the closing price of $1.42. Within the past 52 weeks, VYNE’s price has moved between $0.85 and $4.30.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 65.87% over the last five years. The company achieved an average annual earnings per share of -10.14%. With a float of $13.63 million, this company’s outstanding shares have now reached $15.96 million.
The firm has a total of 13 workers. Let’s measure their productivity. In terms of profitability, gross margin is 65.95%, operating margin of -7414.88%, and the pretax margin is -6969.42%.
VYNE Therapeutics Inc (VYNE) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of VYNE Therapeutics Inc is 18.19%, while institutional ownership is 36.72%. The most recent insider transaction that took place on Jan 15 ’25, was worth 43,800. In this transaction Director of this company bought 15,000 shares at a rate of $2.92, taking the stock ownership to the 51,472 shares.
VYNE Therapeutics Inc (VYNE) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -10.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.71% during the next five years compared to 65.87% growth over the previous five years of trading.
VYNE Therapeutics Inc (NASDAQ: VYNE) Trading Performance Indicators
VYNE Therapeutics Inc (VYNE) is currently performing well based on its current performance indicators. A quick ratio of 4.47 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 36.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.99, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of VYNE Therapeutics Inc (VYNE)
Analysing the last 5-days average volume posted by the [VYNE Therapeutics Inc, VYNE], we can find that recorded value of 0.55 million was better than the volume posted last year of 0.36 million. As of the previous 9 days, the stock’s Stochastic %D was 23.25%.
During the past 100 days, VYNE Therapeutics Inc’s (VYNE) raw stochastic average was set at 22.97%, which indicates a significant decrease from 39.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.2394 in the past 14 days, which was higher than the 0.1534 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1847, while its 200-day Moving Average is $2.0899. Now, the first resistance to watch is $1.4333. This is followed by the second major resistance level at $1.5367. The third major resistance level sits at $1.6133. If the price goes on to break the first support level at $1.2533, it is likely to go to the next support level at $1.1767. Should the price break the second support level, the third support level stands at $1.0733.
VYNE Therapeutics Inc (NASDAQ: VYNE) Key Stats
Market capitalization of the company is 22.16 million based on 15,210K outstanding shares. Right now, sales total 500 K and income totals -39,830 K. The company made 200 K in profit during its latest quarter, and -8,610 K in sales during its previous quarter.
